ArticleScience translational medicine2021

Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade.

Ravi B Patel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.